Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Operating Margin (2020 - 2025)

Xeris Biopharma Holdings' Operating Margin history spans 6 years, with the latest figure at 19.55% for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 1675.0% year-over-year to 19.55%, compared with a TTM value of 8.53% through Dec 2025, up 2510.0%, and an annual FY2025 reading of 8.53%, up 2510.0% over the prior year.
  • Operating Margin for Q4 2025 was 19.55% at Xeris Biopharma Holdings, up from 9.05% in the prior quarter.
  • The five-year high for Operating Margin was 19.55% in Q4 2025, with the low at 289.55% in Q2 2021.
  • Average Operating Margin over 5 years is 70.62%, with a median of 37.52% recorded in 2023.
  • Year-over-year, Operating Margin crashed -7402bps in 2021 and then skyrocketed 21480bps in 2022.
  • Tracing XERS's Operating Margin over 5 years: stood at 225.26% in 2021, then surged by 80bps to 45.77% in 2022, then surged by 52bps to 22.17% in 2023, then soared by 113bps to 2.79% in 2024, then soared by 600bps to 19.55% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Operating Margin are 19.55% (Q4 2025), 9.05% (Q3 2025), and 6.27% (Q2 2025).